HIV budding Color

Study indicates potential breakthrough HIV drug

French biotech Abivax might be on the verge of HIV cure and prevention discovery, after achieving a significant reduction of viral load patients during the first 28 days of treatment.

Gilead Sciences

Gilead's latest hep C combo approved in US

Gilead’s new hepatitis C triple therapy Vosevi has been approved in the US, and will largely meet the needs of patients with difficult to treat forms of the disease.